...
机译:免疫生物标志物作为核心核酸核糖患者核心(T)IDE模拟治疗后结果的结果指标。
Department of Clinical and Experimental SciencesUniversity of SouthamptonSouthampton UK;
2nd Academic Department of Internal MedicineHippokration General Hospital of AthensAthens Greece;
2nd Academic Department of Internal MedicineHippokration General Hospital of AthensAthens Greece;
Department of Clinical and Experimental SciencesUniversity of SouthamptonSouthampton UK;
2nd Academic Department of Internal MedicineHippokration General Hospital of AthensAthens Greece;
2nd Academic Department of Internal MedicineHippokration General Hospital of AthensAthens Greece;
Department of Clinical and Experimental SciencesUniversity of SouthamptonSouthampton UK;
Department of Clinical and Experimental SciencesUniversity of SouthamptonSouthampton UK;
Department of Clinical and Experimental SciencesUniversity of SouthamptonSouthampton UK;
Department of Clinical and Experimental SciencesUniversity of SouthamptonSouthampton UK;
Department of Clinical and Experimental SciencesUniversity of SouthamptonSouthampton UK;
Academic Department of GastroenterologyLaiko General Hospital of AthensAthens Greece;
Academic Department of GastroenterologyLaiko General Hospital of AthensAthens Greece;
Department of Clinical and Experimental SciencesUniversity of SouthamptonSouthampton UK;
chronic hepatitis B; nucleos(t)ide analogues; treatment discontinuation;
机译:免疫生物标志物作为核心核酸核糖患者核心(T)IDE模拟治疗后结果的结果指标。
机译:在HB HB EAG Seroconversion后,在白种人乙型肝炎患者中停止核核苷酸(T)IDE模拟处理与高复发率和致命结果相关
机译:HBEAG阴性慢性乙型肝炎患者中核(T)IDE类似物(NAS)停药后的持续反应(SR)预测的免疫参数
机译:慢性乙型肝炎患者IFN-α2b对PBMC HBV-DNA,血清和CD25诱导的负面影响
机译:HBeAg阴性慢性乙型肝炎病毒感染的病毒突变和自然病程。
机译:慢性乙型肝炎患者HBeAg阴性的核苷酸(t)ide类似物停用后的长期结果
机译:慢性乙型肝炎患者HBeAg阴性的核苷酸(t)ide类似物停用后的长期结果